Turning Point Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2013-10-08
- Employees
- 251
- Market Cap
- -
Clinical Trials
19
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
Study of Repotrectinib and CYP450 probe Cocktail in Patients with locally advanced or Metastatic Tyrosine Kinase Inhibitors (TKI)-Pretreated ROS1-Positive Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Bristol-Myers Squibb Services Unlimited Company
- Target Recruit Count
- 17
- Registration Number
- 2024-511030-12-00
- Locations
- 🇫🇷
Institut Bergonie, Bordeaux, France
🇫🇷Centre Hospitalier Universitaire De Rennes, Rennes, France
🇫🇷Centre Hospitalier Regional De Marseille, Marseille, France
A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients
- Conditions
- Locally Advanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Turning Point Therapeutics, Inc.
- Registration Number
- NCT05828277
- Locations
- 🇺🇸
Gabrail Cancer Research Center, Canton, Ohio, United States
🇪🇸Local Institution - 4103, Madrid, Spain
A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors
- Conditions
- KRAS Mutation-Related TumorsAdvanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2021-10-08
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Turning Point Therapeutics, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT05071183
- Locations
- 🇺🇸
Local Institution - 2101, California City, California, United States
🇺🇸Local Institution - 2109, California City, California, United States
🇺🇸Local Institution - 2106, Denver, Colorado, United States
Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Turning Point Therapeutics, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT05001516
- Locations
- 🇺🇸
Local Institution - 0013, Duarte, California, United States
🇺🇸Local Institution - 0017, Fullerton, California, United States
🇺🇸Local Institution - 0012, Lafayette, Indiana, United States
A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC
- Conditions
- Non Small Cell Lung CancerNon-Small Cell Lung CancerNSCLCAdvanced Solid TumorMetastatic Solid TumorALK Gene Mutation
- Interventions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2023-05-26
- Lead Sponsor
- Turning Point Therapeutics, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT04849273
- Locations
- 🇺🇸
Local Institution - 2104, Orange, California, United States
🇺🇸Local Institution - 2105, Aurora, Colorado, United States
🇺🇸Local Institution - 2106, Boston, Massachusetts, United States
- Prev
- 1
- 2
- Next